Healthcare Services

Visceral Leishmaniasis Market Future Outlook Showing Expansion Toward $1.38 Billion by 2030

April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Visceral Leishmaniasis Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The visceral leishmaniasis market has demonstrated substantial growth over recent years. Its size is anticipated to expand from $1.06 billion in 2025 to $1.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. This historical growth can be linked to factors such as the widening prevalence of the endemic disease, intensified public health awareness efforts, the availability of proven antiparasitic treatments, the development of hospital-based treatment programs, and support from international health organizations.

The market for visceral leishmaniasis is projected to experience robust expansion in the coming years. This market is anticipated to reach $1.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. Several factors are contributing to this growth during the forecast period, including increased investments in innovative therapeutics, a heightened emphasis on developing vaccines and immunotherapies, broader adoption of molecular diagnostics, increased government funding aimed at disease elimination, and improved access to treatment in regions where the disease is prevalent. Key trends identified for the forecast period encompass a greater uptake of advanced diagnostic methods, an increased application of combination drug therapies, a stronger emphasis on identifying the disease at early stages, the expansion of public health screening initiatives, and greater investment dedicated to ensuring treatment accessibility.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp

What Drivers Are Influencing The Visceral Leishmaniasis Market?

The growth of the visceral leishmaniasis market is projected to be propelled by the increasing incidence of malnutrition. Malnutrition is a health condition characterized by an insufficient or improper balance of nutrient intake necessary for healthy physiological processes. The rise in malnutrition is attributed to food insecurity, which limits access to nutritious meals, leading to undernourishment and deficiencies in micronutrients that weaken the immune system. When immune function is impaired by malnutrition, the body becomes more susceptible to infections such as visceral leishmaniasis. Inadequate nutrient levels compromise defense mechanisms, thereby increasing the risk of severe disease and complications. For instance, in July 2024, the United Nations Children’s Fund (UNICEF), a U.S.-based specialized agency, indicated that around 733 million people were undernourished globally in 2023. Hence, the escalating issue of malnutrition is driving the expansion of the visceral leishmaniasis market.

What Major Segment Divisions Exist Within The Visceral Leishmaniasis Market?

The visceral leishmaniasis market covered in this report is segmented –

1) By Treatment: Antiparasitic, Antifungal, Other Treatments

2) By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods

3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Antiparasitic: Pentavalent Antimonials, Miltefosine, Paromomycin, Sitamaquine, Combination Therapy

2) By Antifungal: Amphotericin B, Liposomal Amphotericin B (AmBisome), Azoles, Echinocandins, Polyenes

3) By Other Treatments: Immunotherapy, Monoclonal Antibodies, Vaccine-Based Approaches, Photodynamic Therapy, Gene Therapy

What Trends Are Affecting The Expansion Of The Visceral Leishmaniasis Market?

Companies operating in the visceral leishmaniasis market are primarily focused on developing enhanced treatment options, such as antiparasitic drugs, to improve their effectiveness and increase patient availability, especially in regions most affected. Antiparasitic drugs are medications employed to treat parasite-induced infections by targeting the parasite’s biological functions, thereby interrupting its growth, replication, or survival within the host. For instance, in February 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, obtained World Health Organization (WHO) prequalification approval for the active pharmaceutical ingredient (API) and formulation of miltefosine, used for treating leishmaniasis or kala-azar. Miltefosine is an oral antiparasitic medication that functions by disrupting the parasite’s cell membrane and interfering with its metabolism, leading to cell death. It also suppresses parasite growth and survival, making it an effective oral treatment option for visceral leishmaniasis or kala azar.

Which Companies Are Leading Innovation In The Visceral Leishmaniasis Market?

Major companies operating in the visceral leishmaniasis market are Pfizer Inc., GSK plc, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd., Xellia Pharmaceuticals, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, Sanofi SA, Bharat Serums and Vaccines Limited, Emcure Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Ipca Laboratories Limited, Intas Pharmaceuticals Limited, Macleods Pharmaceuticals Limited, Mankind Pharma Limited, Alembic Pharmaceuticals Limited

Read the full visceral leishmaniasis market report here:

https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Visceral Leishmaniasis Market?

North America was the largest region in the visceral leishmaniasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Visceral Leishmaniasis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23573&type=smp

Browse Through More Reports Similar to the Global Visceral Leishmaniasis Market 2026, By The Business Research Company

Anticoagulant Global Market Report

https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

Psoriasis Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Veterinary Parasiticides Global Market Report

https://www.thebusinessresearchcompany.com/report/veterinary-parasiticides-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795